Are you interested in Bentrio from a professional perspective?
Science and data behind Bentrio
Development of Bentrio has been inspired by the increasing understanding of the key role of the nose in the transmission of viral infections, in particular of SARS-CoV-2, which can cause COVID-19. Our dedicated scientists applied their expertise in formulation development and nasal spray delivery. They swiftly identified the key components to create and optimize AM-301, which then became Bentrio.
Through extensive pre-clinical and clinical testing, safety, tolerability and efficacy of Bentrio were evaluated and established. The protective effects have been demonstrated under relevant testing conditions for the two main indications of use in viral infection and allergy.
Bentrio shows statistically significant benefits in a controlled clinical allergy study
This graph shows the rating of allergic rhinitis symptoms (Total Nasal Symptom Score) by volunteers while they were exposed for four hours to grass pollen in a so-called challenge chamber. Blue line: participants receiving one dose of Bentrio prior to entering the chamber. Grey line: no protection provided. Application of Bentrio resulted in a statistically significant reduction of allergy symptoms.
Bentrio reduces SARS-CoV-2 viral load in pre-clinical testing of human nasal epithelium model
This graph shows the SARS-CoV-2 viral load in a model of nasal epithelium from human donors following infection. Treatment with Bentrio started 10 minutes prior to inoculation and was repeated daily for 4 days. After 96 hours, the viral load was 99.4% lower with Bentrio treatment compared to controls (treated only with saline solution).
Our scientists continue to test Bentrio in further studies. Find more information about Bentrio’s pre-clinical and clinical development program here: